AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01554826 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine
Description: 0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
Study NCT03737565 — intervention group
Intervention type: DEVICE
Intervention: Optimax stent®
Description: Percutaneous coronary intervention with Optimax stent®
Study NCT01775436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAmily-CEntered Advance Care Planning
Description: Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care \& prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have.
Study NCT01775436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FAmily-CEntered Advance Care Planning
Description: Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care \& prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have.
Study NCT01775436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living Control
Description: Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention.
Study NCT01775436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Control
Description: Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention.
Study NCT01462318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 5 mg
Study NCT01462318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 200 mg
Study NCT03006588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-FNA for RPLN in NPC patients
Description: An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
Study NCT03387215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral
Study NCT01462318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-warfarin
Description: 10 mg
Study NCT01462318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: 10 mg
Study NCT01462318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg
Study NCT01462318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 30 mg
Study NCT01462318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab)
Description: 150 mg in 1 ml PFS
Study NCT00725114 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetrodotoxin
Description: 30 µg twice daily for 4 days
Study NCT00725114 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL subcutaneous injection twice daily for 4 days
Study NCT01103622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet bd, step-wise increased dosage
Study NCT03387215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT03021460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03021460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03021460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00207350 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Interstitial Laser Therapy
Description: Device
Study NCT01317485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage and drainage
Description: \[CLOSED\] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~\*\*\*This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues
Study NCT01317485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidectomy with primary anastomosis
Description: \[OPEN\] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
Study NCT00838006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart rate variability biofeedback
Description: Heart rate variability biofeedback, 3 session plus handheld device
Study NCT00838006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training
Description: Cognitive bias modification training - 3 session plus handheld device
Study NCT01291966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Study NCT03986125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness & Expression Therapy
Description: emotion-focused
Study NCT00838006 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Subjects received iPod without a study app and no additional resilience training
Study NCT03986125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training
Description: meditation training and practice
Study NCT01267474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.~All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.~Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.~All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts.
Study NCT01267474 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: The control group received only three one-hour general sessions on health issues.
Study NCT03984721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Amyloidosis typing using mass spectrometry-based proteomics
Description: Amyloidosis typing using nanoLC-MS/MS method
Study NCT00800800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 40 mg, oral, single dose
Study NCT00800800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, single dose
Study NCT02098694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy follow-up
Description: Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise.
Study NCT00984880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3043
Description: Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
Study NCT02993055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin
Study NCT02993055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03076918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEXITHERALIGHT PDT
Description: Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
Study NCT03076918 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aktilite® Galderma
Description: Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
Study NCT00792701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00792701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT03864809 — intervention group
Intervention type: BEHAVIORAL
Intervention: sleep disturbance
Description: we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group
Study NCT03213977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DA-EPOCH
Description: R-DA-EPOCH-21 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
Study NCT03213977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CEOP90
Description: R-CEOP90 treatment for DLBCL patients between 16 to 60 years with high risk. Patients who meet the criteria for ASCT after reaching CR or PR will undergo ASCT, while those who do not meet the criteria or refuse to undergo ASCT, will continue with 2 cycles of immunochemotherapy.
Study NCT01214317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: plasmapheresis
Description: 3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
Study NCT01403831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily text messages
Description: 2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
Study NCT02528968 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational Package
Description: Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
Study NCT03404271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-hydroxy beta-methylbutyrate
Description: 3 grams per day of the calcium salt form of beta-hydroxy beta-methylbutyrate (HMB).
Study NCT03404271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: Performing supervised resistance training three times per week.
Study NCT03404271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Performing supervised resistance training three times per week.
Study NCT03404271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein Supplementation
Description: Consuming a protein supplement daily.
Study NCT03404271 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: Consuming a protein supplement daily.
Study NCT03404271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding
Description: Consuming all calories within a specified 8-hour period of time each day.
Study NCT02227303 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle modification instructional and motivational sessions
Study NCT03118011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No smoking
Description: No smoking
Study NCT03118011 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smoking
Description: Ability to go out to smoke
Study NCT03495453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS
Description: Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is a small catheter with a diamond crown. The doctor inserts it at the groin and advances into the leg.The OAS works by spinning around inside the artery to sand down the buildup of material along the artery walls while leaving the healthy vessel behind.
Study NCT03495453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device
Description: HawkOne Directional Atherectomy System (DAS) also is the small catheter with cutting device. Doctor slowly and smoothly advances it across the blockage in your artery and shaves the plaque from the vessel wall and collects it in the reservoir.
Study NCT01718626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1+Docetaxel
Description: Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
Study NCT01718626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1+Docetaxel followed by S1
Description: Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
Study NCT00553553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulphate
Description: Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
Study NCT00553553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride, remifentanil hydrochloride
Description: Pre-induction intrathecal morphine HCl (\< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure
Study NCT01790009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol rich drink
Study NCT01790009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 2x500 mg Acetaminophen
Study NCT03944070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.
Study NCT03636568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Restricted Group
Description: Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients \< 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients >100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh \<=100 kg and 1200 cc/24 hours for patients who weigh > 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:~1. Serum Na level must be \< 145 mEq/l~2. Patient should be taking fluids by mouth~3. Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated.
Study NCT02356146 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus C12
Study NCT04603040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Experimental group:~Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), In a cycle of 3 weeks (21 days), until occurrence of termination event specified in the protocol.
Study NCT00347412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is dosed at 200 mg/m2, as a 3 hour infusion.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.
Study NCT00347412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel is dosed at 200 mg/m2, as a 3 hour infusion.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.
Study NCT00347412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV-002
Description: * Two 60 mg intravenous boli given 3 hours apart administered the day prior to the first administration of paclitaxel and carboplatin cycle one~* For each nominal 21-day paclitaxel and carboplatin cycle:~  * 60 mg given intravenously on Day 1, given one hour prior to paclitaxel and carboplatin~ * followed by 60 mg subcutaneously daily for the next 20 days. If there is a delay in chemotherapy cycles, the patient will continue with daily, subcutaneous administration of NOV-002 until the next cycle of chemotherapy begins~Patients randomized to NOV-002 Group A, will receive NOV-002 until disease progression, unacceptable NOV-002 related toxicity, or discontinuation of paclitaxel and carboplatin, whichever comes first.
Study NCT00347412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is dosed at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.~The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel, as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.
Study NCT00347412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is dosed at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.~The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel, as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.